Pharmaceutical technology company XtalPi has formed a strategic research alliance with Pfizer to develop a physics and artificial intelligence (AI) powered molecular modelling platform for drug discovery.

Intended to allow precise modelling of drug-like small molecules, the hybrid software technology will use a combination of quantum mechanics, machine learning algorithms and cloud computing.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The platform is set to improve both the accuracy and chemical-space coverage of molecular mechanics modelling and the prediction of pharmaceutical properties.

XtalPi co-founder and board chairman Shuhao Wen said: “The collaboration allows us to apply our expertise in molecular modelling, AI, and cloud computing towards improving existing computational methods while exploring new algorithms to address a wide range of drug design challenges.

“We are looking forward to potentially utilising new tools to increase our effectiveness in small molecule drug discovery and development.”

“We look forward to helping expedite research into novel therapeutics as our intelligent digital drug discovery and development platform continues to expand and succeed.”

XtalPi previously collaborated with Pfizer on crystal structure prediction and the latest partnership will boost their computation-based rational drug design and solid-form selection capabilities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The companies intend to provide the academic community with access to certain molecular mechanics parameters generated using public-domain compounds.

Pfizer medicine design head Charlotte Allerton said: The XtalPi collaboration is an opportunity to enhance our computational modelling capabilities

“We are looking forward to potentially utilising new tools to increase our effectiveness in small molecule drug discovery and development.”